Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report

Figures & data

Figure 1 Chest CT findings of Severe Chlamydia psittaci pneumonia. (A–C) March 2, 2022: The day of admission. Large exudative foci in the right lung and a large consolidation shadow in the right lower lung. (D–F) Thirteen day after admission on March 15, 2022. Exudative foci and consolidation shadow in the right lung were less pronounced than those before. (G–I) Twenty-two day after admission on March 24, 2022. Further resorption of the right lung lesion than before. (J–L) April 24, 2022: 1 month after discharge. The lung lesions were largely resorbed, leaving only a small number of fibrous linear opacities.

Figure 2 Body temperature and antimicrobial treatment during hospitalisation with meropenem at 1.0 g ivgtt Q8h (days 1–3), moxifloxacin at 0.4 g ivgtt Qd (days 1–3), oseltamivir at 75 mg po Q12h (days 1–3), and omadacycline at 100 mg ivgtt Q12 h (day 3), 100 mg ivgtt Qd (days 4–14), and 300 mg po Qd (days 15–23).

Figure 3 Change in white blood cell count and neutrophil predominance during hospitalisation.

Figure 4 Change in C-reactive protein and procalcitonin during hospitalisation.

Figure 5 Change in alanine aminotransferase and serum creatinine during hospitalisation.

Figure 6 Change in creatine kinase and lactate dehydrogenase during hospitalisation.

Figure 7 Change in the oxygenation index during hospitalisation.